Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Carl Christoph Schimanski"'
Autor:
Carl Christoph Schimanski, Stefan Kasper, Susanna Hegewisch-Becker, Jan Schröder, Friedrich Overkamp, Frank Kullmann, Wolf Otto Bechstein, Matthias Vöhringer, Robert Öllinger, Florian Lordick, Volker Heinemann, Michael Geißler, Armin Schulz-Abelius, Helga Bernhard, Michael R. Schön, Richard Greil, Peter Galle, Hauke Lang, Irene Schmidtmann, Markus Moehler
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Resection of colorectal liver metastases (CRLM) is a potential curative treatment for patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD). Although long-term survival improved considerably within the last decades, high
Externí odkaz:
https://doaj.org/article/01ad6800ad634d7fad4dd215ec8dfacc
Autor:
Vicki R. Kelley, Andreas Schwarting, Melvin M. Schwartz, Carl Christoph Schimanski, Jörg Kriegsmann, Julia Menke
PDF file - 803K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eace9d08b2cdce9f8531c3c759cdd6c
https://doi.org/10.1158/0008-5472.22389669.v1
https://doi.org/10.1158/0008-5472.22389669.v1
Autor:
Vicki R. Kelley, Andreas Schwarting, Melvin M. Schwartz, Carl Christoph Schimanski, Jörg Kriegsmann, Julia Menke
PDF file - 1.1MB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d5f8818b63926779374c266037e0547
https://doi.org/10.1158/0008-5472.22389684.v1
https://doi.org/10.1158/0008-5472.22389684.v1
Autor:
Sina Buchholz, Thomas Jens Ettrich, Waldemar Uhl, Marko Kornmann, Hana Algül, Helmut Friess, Alexander Koenig, Eike Gallmeier, Manfred P. Lutz, Kai Wille, Carl Christoph Schimanski, Volker Kunzmann, Michael Geissler, Dirk Waldschmidt, Severin Daum, Lukas Perkhofer, Anke C. Reinacher-Schick, Thomas Seufferlein
Publikováno v:
Journal of Clinical Oncology. 41:694-694
694 Background: Perioperative chemotherapy (CTX) in resectable pancreatic adenocarcinoma (rPDAC) is still not considered SoC and data regarding efficacy but also quality of life (QoL) are limited. NEONAX is a prospective, randomized phase II trial in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5d41d9ef80e26b7d627fab4e9206c83
https://doi.org/10.1200/jco.2023.41.4_suppl.694
https://doi.org/10.1200/jco.2023.41.4_suppl.694
Autor:
Thomas Jens Ettrich, Waldemar Uhl, Marko Kornmann, Hana Algül, Helmut Friess, Alexander Koenig, Eike Gallmeier, Manfred P. Lutz, Kai Wille, Carl Christoph Schimanski, Volker Kunzmann, Michael Geissler, Dirk Waldschmidt, Severin Daum, Lisa Blome, Andrea Tannapfel, Lukas Perkhofer, Margaret A. Tempero, Anke C. Reinacher-Schick, Thomas Seufferlein
Publikováno v:
Journal of Clinical Oncology. 40:4133-4133
4133 Background: Perioperative chemotherapy (CTX) in resectable pancreatic ductal adenocarcinoma (PDAC) is still not considered standard of care and data are limited. The NEONAX trial examined gemcitabine (Gem) plus nab-paclitaxel (nab-P), in the per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42a9452b9e813b53f58b6eb5cc79dcaf
https://doi.org/10.1200/jco.2022.40.16_suppl.4133
https://doi.org/10.1200/jco.2022.40.16_suppl.4133